The Importance of Provisional Protection for Biotech Inventions

By Dr Armin Bohmann, Founder and Partner of Bohmann & Loosen, and Dr Ulrich Gerth, Vice President of Equity Corporate Finance at Hypovereinsbank Corporates & Markets

Dr Armin K Bohmann is Founder and Partner of Bohmann & Loosen, which was established in August 2000. Armin was previously Head of the Biotech Department of a leading German law firm specialising in intellectual property. His interests are IP matters related to biotechnology, chemistry and pharmacy; including prosecution, litigation and licensing.

Armin received a Diploma in Molecular Biology from the Technical University of Munich and a Doctorate Degree in Bioprocess and Biochemical Engineering, and spent one year as a postdoctoral in Japan.


Dr Ulrich C Gerth is Vice President of Equity Corporate Finance at HVB Corporates & Markets. He joined the company in April 2000, working in the biotech and life sciences sector on technology, products and business models. He moved to the corporate finance department in July 2001.

Ulrich previously worked as a Consultant for Ernst & Young's life sciences team. He was responsible for pre-IPO evaluations, consultation and market research, and was a co-author of two of their European Life Sciences Reports. After gaining a degree in Biochemistry from the University of Witten/Herdecke, Ulrich obtained his doctorate degree in Molecular Medicine at Oxford University, UK.